Evidence map›Paper›PMID 29538422›Full record

ArticlePloS one2018

Bidesmosidic betulin saponin bearing L-rhamnopyranoside moieties induces apoptosis and inhibition of lung cancer cells growth in vitro and in vivo.

Mouadh Mihoub, André Pichette, Balla Sylla, Charles Gauthier, Jean Legault

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mouadh MihoubChaire de Recherche sur les Agents Anticancéreux d'Origine Naturelle, Laboratoire LASEVE, Université du Québec à Chicoutimi, Département des Sciences Fondamentales, 555 boul. de l'Université, Chicoutimi (Québec), Canada.
André PichetteChaire de Recherche sur les Agents Anticancéreux d'Origine Naturelle, Laboratoire LASEVE, Université du Québec à Chicoutimi, Département des Sciences Fondamentales, 555 boul. de l'Université, Chicoutimi (Québec), Canada.
Balla SyllaChaire de Recherche sur les Agents Anticancéreux d'Origine Naturelle, Laboratoire LASEVE, Université du Québec à Chicoutimi, Département des Sciences Fondamentales, 555 boul. de l'Université, Chicoutimi (Québec), Canada.
Charles GauthierChaire de Recherche sur les Agents Anticancéreux d'Origine Naturelle, Laboratoire LASEVE, Université du Québec à Chicoutimi, Département des Sciences Fondamentales, 555 boul. de l'Université, Chicoutimi (Québec), Canada.
Jean LegaultChaire de Recherche sur les Agents Anticancéreux d'Origine Naturelle, Laboratoire LASEVE, Université du Québec à Chicoutimi, Département des Sciences Fondamentales, 555 boul. de l'Université, Chicoutimi (Québec), Canada.ORCID 0000-0001-6292-6798
Université du Québec à Chicoutimi · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Betulin has a wide range of biological and pharmacological properties with its anticancer activity attracting most of the attention as it offers a possible alternative treatment to chemotherapy. However, betulin's in vivo biological effectiveness is limited by its poor solubility. As such, we synthesized polar glycosylated derivatives to increase its hydrosolubility and enhance its pharmacological properties. Among these synthesized compounds, 28-O-α-l-rhamnopyranosylbetulin 3β-O-α-l-rhamnopyranoside (Bi-L-RhamBet) was assessed for its cytotoxic effects against a suite of lung cancer cell lines. We also investigated its mechanism of action using an A549 lung cancer cell line. Our results showed that Bi-L-RhamBet exhibited potent cytotoxic activity toward lung cancer cell lines including A549, NCI-H2087, NCI-H522, NCI-H1993 NCI-H1755, and LLC1 having IC50 values ranging from 2.9 to 5.9 μM. Moreover, Bi-L-RhamBet (50 mg/kg) significantly inhibited tumor growth with a treatment-to-control ratio (T/C) of 0.54 and a tumor growth inhibition rate of 46% at day 18 (p < 0.05). Microscopic observations of A549 cells, double stained with acridine orange and ethidium bromide, showed apoptotic features. Bi-L-RhamBet induced activation of pro-apoptotic caspases 8, 9, and 3/7 as well as causing DNA fragmentation. Moreover, a marked increase in mitochondrial ROS (mROS) was coupled with a reduction of mitochondrial potential. Interestingly, the presence of mitochondrial electron transport chain (ETC) inhibitors, including rotenone, malonate, and antimycin A, reduced mROS production, and the activation of caspases suggesting that Bi-L-RhamBet disturbs the ETC. Finally, dichloroacetate, a pyruvate dehydrogenase kinase inhibitor potentiated the cytotoxicity of Bi-L-RhamBet against A549 cells. Taken together, these data suggest that Bi-L-RhamBet can induce apoptotic cell death via disturbance of mitochondrial electron transfer chain, reduced ROS production, and decreased membrane potential.

Indexed as

A549 CellsAnimalsApoptosisBetulinic AcidCaspasesCell Line, TumorCell ProliferationDNA FragmentationElectron Transport Chain Complex ProteinsG2 Phase Cell Cycle CheckpointsHumansLung NeoplasmsMaleMembrane Potential, MitochondrialMiceMice, Inbred C57BLbetulinBetulinic AcidCaspasesElectron Transport Chain Complex ProteinsReactive Oxygen SpeciesRhamnoseRotenoneSaponinsTriterpenes

Identifiers

PMID29538422
PMCPMC5851596
OpenAlexW2792766534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.